New insights into role of microenvironment in multiple myeloma

@article{Tricot2000NewII,
  title={New insights into role of microenvironment in multiple myeloma},
  author={Guido Tricot},
  journal={The Lancet},
  year={2000},
  volume={355},
  pages={248-250}
}
  • G. Tricot
  • Published 2000
  • Medicine, Biology
  • The Lancet
Multiple Myeloma (MM) is a malignant disease of terminally differentiated B cells. It most likely originates in a B cell which has traversed the germinal center and has been exposed there extensively to antigens based on the high number of somatic mutations in the complementarity determining regions. The cell of origin is either a plasmablast, or more likely, a memory B-cell. Typically MM goes through different phases from indolent (MGUS, smoldering myeloma) to overt myeloma and then to a… Expand
The molecular pathogenesis of multiple myeloma
TLDR
The genetic heterogeneity of MM is explained, one of the major drivers of disease recurrence, and how this knowledge may influence future diagnostic and therapeutic interventions is proposed. Expand
The Malignant Hierarchy in Multiple Myeloma: Relationships between Malignant Cells and Bone Disease
Multiple myeloma (MM) is an incurable cancer of the bone marrow (BM), with survival of 3–4 years. MM accounts for 1% of all cancers, and 19% of deaths from hematological malignancies. It isExpand
Chromosomal instability and acquired drug resistance in multiple myeloma
TLDR
New insights into the type of CIN seen in multiple myeloma, a blood cancer of terminally differentiated, immunoglobulin-producing B-lymphocytes called plasma cells that remains incurable in the great majority of cases, are reviewed. Expand
Molecular pathogenesis of multiple myeloma.
  • G. Tonon
  • Biology, Medicine
  • Hematology/oncology clinics of North America
  • 2007
TLDR
Recent and ongoing high-resolution genomic studies are leading the way toward a more refined and conclusive understanding of the pathogenesis of multiple myeloma. Expand
A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration
TLDR
An improved understanding of high-risk disease, tumor heterogeneity, and clonal evolution will guide future therapies and may ultimately lead towards a cure for multiple myeloma. Expand
A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
TLDR
A way to drive the clinical management of the disease based on its detailed biological features more than surrogates of disease burden is envisioned, by integrating an evolutionary view of myeloma biology with the recent acquisitions on its clonal heterogeneity. Expand
Signalling and survival pathways in multiple myeloma.
TLDR
A comprehensive knowledge of the signalling and survival pathways should pinpoint additional molecular targets and lead to the development of novel and hopefully more effective treatment strategies for multiple myeloma. Expand
Significance of Some Proliferation Markers and Some Prognostic Factors in Patients with Multiple Myeloma and their Impact on the Patients' Survival.
TLDR
High levels of BAFF were found to improve patients' survival and BAFF and IL-6 can be considered probable diagnostic markers for MM. Expand
The role of microenvironment and immunity in drug response in leukemia.
TLDR
The targeting of the microenvironment by leukemia cells to create an environment more suitable for cancer progression is described and the role of soluble factors, drug transporters, microvesicles, as well as the importance of direct cell-cell contact are discussed. Expand
Significance of Proliferation Markers and Prognostic Factors in Egyptian Patients with Multiple Myeloma.
TLDR
High levels of BAFF were found to improve patients' survival and BAFF and IL-6 can be considered probable diagnostic markers for MM. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 18 REFERENCES
Multiple myeloma: increasing evidence for a multistep transformation process.
TLDR
This review intends to propose a model of a stepwise malignant transformation during MM pathogenesis, and diagnostic and therapeutic implications of this model will be discussed. Expand
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
TLDR
A possible direct anti-tumor effect in myeloma patients treated with bisphosphonates may participate in their significantly increased survival, which should now be further tested in clinical trials. Expand
Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
TLDR
Findings indicate that the progression of plasma cell tumors is accompanied by an increased angiogenic and invasive potential of bone marrow plasma cells, which is dependent, at least in part, by FGF-2 and MMP-2 production. Expand
Antitumor activity of thalidomide in refractory multiple myeloma.
TLDR
Thalidomide can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy, and is active against advancedMyeloma. Expand
Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide.
TLDR
Exposure to chemotherapeutic agents may enhance BCL-2 expression in surviving myeloma cells and contribute to acquired chemoresistance. Expand
Expression of bcl-xL can confer a multidrug resistance phenotype.
TLDR
Data show that bcl-XL protects cells from a wide variety of apoptotic stimuli, acts in multiple positions within the cell cycle, and confers a multidrug resistance phenotype. Expand
Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells
TLDR
In a system of apoptosis by growth factor deprivation on myeloma cells, it was shown that the effect of B cl‐2 seemed minimal whereas Mcl‐1 and Bcl‐xL were tightly regulated by interleukin (IL)‐6. Expand
Human myeloma cells express the CD38 ligand CD31
TLDR
Flow cytometry and immunocytochemistry data indicated that PC malignancies co‐expressed high levels of both CD38 and its ligand CD31, with the exception of plasmablastic MM and PCL. Expand
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.
TLDR
The data suggest that the NF-kappa B site is one of the essential regulatory elements for MM cell adhesion-induced IL-6 transcription in BMSCs, and may provide new therapeutic strategies based on interruption of IL- 6 mediated tumor cell growth. Expand
Cell biology of the osteoclast.
  • G. Roodman
  • Chemistry, Medicine
  • Experimental hematology
  • 1999
TLDR
The osteoclast is a hematopoietic cell derived from CFU-GM and branches from the monocyte-macrophage lineage early during the differentiation process, and current research is beginning to delineate the signaling pathways involved in osteoclastic bone resorption and osteoc last formation in response to cytokines and hormones. Expand
...
1
2
...